BioMarin Pharma (BMRN) Tops Q1 EPS by 32c, Offers Guidance
BioMarin Pharma (NASDAQ: BMRN) reported Q1 EPS of ($0.53), $0.32 better than the analyst estimate of ($0.85). Revenue for the quarter came in at $236.7 million versus the consensus estimate of $240.21 million.
2016 Financial Guidance
Revenue Guidance ($ in millions)
| Item | ||||
| ProvidedFebruary 25, 2016 | Updated April 28, 2016 | |||
| Total BioMarin Revenues | $1,050 to $1,100 | Unchanged | ||
| Vimizim Net Product Revenue | $300 to $330 | $315 to $340 | ||
| Naglazyme Net Product Revenue | $290 to $320 | Unchanged | ||
| Kuvan Net Product Revenue | $320 to $350 | Unchanged | ||
Select Income Statement Guidance ($ in millions, except percentages)
| Item | ||||
| ProvidedFebruary 25, 2016 | Updated April 28, 2016 | |||
| Cost of Sales (% of Total Revenue) | 18.0% to 19.0% | Unchanged | ||
| Selling, General and Admin. Expense | $470 to $490 | Unchanged | ||
| Research and Development Expense | $680 to $720 | Unchanged | ||
| Non - GAAP Net Loss | $(75) to $(100) | Unchanged | ||
| GAAP Net Loss | $(400) to $(430) | $(355) to $(385)* |
For earnings history and earnings-related data on BioMarin Pharma (BMRN) click here.